Genzyme withdraws offer for development partnership
This article was originally published in Clinica
US biotechnology company Genzyme has withdrawn its offer to acquire, in a stock swap, all the assets of Genzyme Development Partners, also known as the Surgical Aids Partnership). Genzyme had offered to purchase the partnership in February for $93 million in Genzyme shares (see Clinica No 691, p 10).
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.